Tammie Moore, NP
Family · Newark, DENPI 1447515515
Payments from drug & device makers
Across 85 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$395
- Takeda Pharmaceuticals U.S.A., Inc.$254
- Johnson & Johnson$203
- Phathom Pharmaceuticals, Inc.$172
- Sanofi$112
- AbbVie$101
- plus $524 from 14 others
What the payments were for
- Food & beverage$1,759100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $395 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $254 |
| Johnson & Johnson(2 entities) | 9 | $203 |
| Phathom Pharmaceuticals, Inc. | 13 | $172 |
| Sanofi | 4 | $112 |
| AbbVie | 5 | $101 |
| Ardelyx, Inc. | 4 | $83 |
| Lilly USA, LLC | 4 | $82 |
| Aimmune Therapeutics, Inc. | 2 | $54 |
| Merck | 3 | $53 |
| Fresenius Kabi USA, LLC | 2 | $37 |
| Pfizer | 2 | $31 |
| Mallinckrodt Hospital Products Inc. | 1 | $29 |
| Madrigal Pharmaceuticals | 1 | $27 |
| Bioprotect Medical, Inc. | 1 | $26 |
| Axonics, Inc. | 1 | $24 |
| Novo Nordisk | 1 | $24 |
| Amgen | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
How this compares
$1,759 in reported general payments places this provider in the 75th percentile of 523 family providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omeprazole | 18 | $173 |
Paid to pharmacies, not to this prescriber.
Other family in Newark
- Kathy GallagherNewark$53K
- Jodie DelesioNewark$50K
- Melanie HiesterNewark$9K
- Samatha GrayNewark$9K
- Byron MayNewark$8K
- Clare MatisNewark$8K
- Christine MazzolaNewark$7K
- Kelsey FrybergerNewark$7K
- Colleen AllenNewark$7K
- Mallory KowalskiNewark$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.